MedPath

Itraconazole

Generic Name
Itraconazole
Brand Names
Sporanox, Tolsura
Drug Type
Small Molecule
Chemical Formula
C35H38Cl2N8O4
CAS Number
84625-61-6
Unique Ingredient Identifier
304NUG5GF4
Background

One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.

Indication

For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

Associated Conditions
Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
Associated Therapies
-

A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants

Phase 1
Not yet recruiting
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: GSK3923868
Drug: Itraconazole
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
20
Registration Number
NCT06597500
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: MK-1708
Drug: Itraconazole
First Posted Date
2024-09-19
Last Posted Date
2024-12-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
12
Registration Number
NCT06586606
Locations
🇺🇸

QPS-MRA, LLC ( Site 0001), South Miami, Florida, United States

A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers

Phase 1
Completed
Conditions
Not Determined
Interventions
First Posted Date
2024-08-07
Last Posted Date
2024-11-27
Lead Sponsor
BeiGene
Target Recruit Count
30
Registration Number
NCT06543043
Locations
🇺🇸

Quotient Sciences, Miami, Florida, United States

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

Phase 1
Not yet recruiting
Conditions
Healthy
Interventions
First Posted Date
2024-08-07
Last Posted Date
2024-10-11
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT06541678
Locations
🇧🇪

Pfizer Clinical Research Unit - Brussels, Bruxelles, Bruxelles-Capitale, Belgium

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

Phase 1
Recruiting
Conditions
Healthy Adults
Interventions
First Posted Date
2024-07-11
Last Posted Date
2024-07-11
Lead Sponsor
Corcept Therapeutics
Target Recruit Count
20
Registration Number
NCT06495944
Locations
🇺🇸

Site 01, Baltimore, Maryland, United States

A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2024-07-10
Last Posted Date
2024-10-11
Lead Sponsor
AstraZeneca
Target Recruit Count
17
Registration Number
NCT06494644
Locations
🇩🇪

Research Site, Berlin, Germany

A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers

Phase 1
Not yet recruiting
Conditions
Healthy
Interventions
First Posted Date
2024-07-09
Last Posted Date
2024-07-09
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Target Recruit Count
36
Registration Number
NCT06492525
Locations
🇨🇳

The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2024-05-20
Last Posted Date
2024-05-20
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
8
Registration Number
NCT06421714
Locations
🇺🇸

PPD, Austin, Texas, United States

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

Phase 2
Terminated
Conditions
Opioid Use Disorder
Interventions
First Posted Date
2024-05-09
Last Posted Date
2024-11-21
Lead Sponsor
AstraZeneca
Target Recruit Count
15
Registration Number
NCT06406400
Locations
🇺🇸

Research Site, Baltimore, Maryland, United States

A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults

Phase 1
Completed
Conditions
Pain
Interventions
First Posted Date
2024-04-30
Last Posted Date
2024-08-01
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
42
Registration Number
NCT06392659
Locations
🇬🇧

MAC Clinical Research, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath